In a big milestone for the nascent psychedelics industry, Peter Thiel-backed pharmaceutical company Compass Pathways, filed to go public on the NASDAQ.
BNN Bloomberg
- It plans to use the proceeds to fund clinical trials for psilocybin as a treatment for depression.
